FTHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Faeth Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$19.44+0.64 (+3.40%)
Close on Oct 19, 2026
- Market cap
- $109.70M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$7.74 (+66.15%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $109.70M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.63
- Dividend yield
- –
- Free cash flow yield
- -30.87%
Fundamentals
- Net income
- -$195.53M
- EPS, diluted
- -$141.65
- Free cash flow
- -$33.86M
- Book value per share
- $30.65
- Diluted shares
- 6M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
-$198.82M
Net income
-$195.53M
EPS, diluted
-$141.65
Free cash flow
-$33.86M
Reported periodTrailing twelve months